Clinical importance of VEGFC and PD-L1 co-expression in lung adenocarcinoma patients
Clinical importance of VEGFC and PD-L1 co-expression in lung adenocarcinoma patients
复制标题
肺腺癌患者中 VEGFC 和 PD-L1 共表达的临床重要性
DOI：
10.1111/1759-7714.13354
复制
发表时间：
2020
期刊：
影响因子：
2.9
通讯作者：
Li Kai
中科院分区：
文献类型：
--
作者：
Qin Tingting;Xia Junling;Liu Shaochuan;Wang Jing;Liu Hailin;Zhang Yan;Jia Yanan;Li Kai
背景血管内皮生长因子C（VEGFC）是新近发现的一种免疫调节剂，它能调节免疫系统，使肿瘤细胞更容易逃避免疫监视。有证据表明，程序性细胞死亡配体1（PD-L1）也可以抑制免疫反应。然而，VEGFC和PD-L1共表达对肺腺癌患者预后的临床意义尚未确定。方法回顾性分析2011年12月至2016年9月在天津医科大学附属肿瘤医院接受手术的114例肺腺癌患者。收集组织标本进行VEGFC和PD-L1的免疫组化，并用H评分系统进行分析。结果在这项研究中，57例（50.0%）和47例（41.2%）患者被归类为VEGFC高表达和PD-L1高表达。在33例（28.9%）患者中观察到共表达。此外，VEGFC与PD-L1呈正相关（P= 0.0398，r = 0.1937）。在单变量分析中，VEGFC高表达组和PD-L1高表达组的无进展生存期（PFS）和总生存期（OS）分别显著更差。此外，VEGFC/PD-L1共表达组的OS（P= 0.03）和PFS生存期（P= 0.01）均低于其他组。结论：VEGFC/PD-L1共表达可预测肺腺癌患者的OS和PFS。VEGFC和PD-L1的共表达可能是肺腺癌患者的重要预后因素。要点VEGFC/PD-L1共表达预测肺腺癌切除患者的生存率较低。VEGFC/PD-L1共表达可作为预后指标，并为临床治疗中筛选抗VEGFC和抗PD-L1联合治疗的最佳人群提供理论可能性。
BackgroundVascular endothelial growth factor C (VEGFC), an activator of lymphangiogenesis, is newly identified as an immunomodulator which can regulate the immune system so that tumor cells more easily escape immune surveillance. Evidence has shown programmed cell death‐ligand 1 (PD‐L1) can also suppress the immune response. Nevertheless, the clinical significance of co‐expression of VEGFC and PD‐L1 for predicting outcomes in patients with lung adenocarcinoma has not yet been determined.MethodsA total of 114 patients with lung adenocarcinoma who underwent surgeries at Tianjin Medical University Cancer Institute and Hospital between December 2011 and September 2016 were retrospectively reviewed. Tissue specimens were collected for immunohistochemistry of VEGFC and PD‐L1 which were analyzed with an H‐score system.ResultsIn this study, 57 (50.0%) and 47 (41.2%) patients were classified as VEGFC high expression and PD‐L1 high expression. Co‐expression was observed in 33 (28.9%) patients. In addition, a positive correlation was found between VEGFC and PD‐L1 (P= 0.0398, r = 0.1937). In a univariate analysis, both progression‐free survival (PFS) and overall survival (OS) were significantly worse in the VEGFC high expression group and the PD‐L1 high expression group, respectively. Furthermore, VEGFC/PD‐L1 co‐expression showed a worse OS (P= 0.03) and PFS survival (P= 0.01) than the other groups.ConclusionsTaken together, these results indicate that VEGFC/PD‐L1 co‐expression can forecast both poor OS and PFS in patients with resected lung adenocarcinoma. Co‐expression of VEGFC and PD‐L1 may serve as a significant prognostic factor for patients with lung adenocarcinoma.Key pointsVEGFC/PD‐L1 co‐expression forecasts poor survival in patients with resected lung adenocarcinoma. VEGFC/PD‐L1 co‐expression may be used as a prognostic indicator and provide the theoretical possibility to screen the optimal population with a combination of anti‐VEGFC and anti‐PD‐L1 therapy in the clinical treatment.